|
3-Methoxyeticyclidine (3-MeO-PCE) is a dissociative anesthetic drug that has been sold online as a designer drug. The activity of 3-MeO-PCE in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCE was qualitatively similar to PCP. On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of Methoxetamine should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCE. This report also described the receptor binding profile of Methoxetamine and three additional dissociatives 3-MeO-PCP, 4-MeO-PCP and 3-MeO-PCE, showing them to have significant affinity for the PCP site of NMDAR and was later published in more detail. 3-MeO-PCE has a Ki of 61 nM for the NMDA receptor, 115 nM for the serotonin transporter, 4519 nM for the sigma receptor and 525 nM for the sigma receptor.〔 ==See also== * 3-HO-PCP * 3-MeO-PCMo * Arylcyclohexylamine * Ketamine * Methoxyketamine * Eticyclidine 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「3-MeO-PCE」の詳細全文を読む スポンサード リンク
|